| ID | Sequence | Length | GC content |
|---|---|---|---|
| ACAAGUGUGAAGCCUGGAAGCCGGCGGGUGCCGCUGUGUAGGAAAGAAG… | 1356 nt | 0.6084 | |
| AAUUCUACCCCCCUUGGUGCCAACAGAUGAGGUUCACAAUCUCUUCCAC… | 1544 nt | 0.5855 | |
| AAUUCUACCCCCCUUGGUGCCAACAGAUGAGGUUCACAAUCUCUUCCAC… | 1644 nt | 0.5827 | |
| AAUUCUACCCCCCUUGGUGCCAACAGAUGAGGUUCACAAUCUCUUCCAC… | 1523 nt | 0.5883 |
The protein encoded by this gene is a surface antigen that is preferentially expressed on monocytes/macrophages. It cooperates with other proteins to mediate the innate immune response to bacterial lipopolysaccharide, and to viruses. This gene has been identified as a target candidate in the treatment of SARS-CoV-2-infected patients to potentially lessen or inhibit a severe inflammatory response. Alternative splicing results in multiple transcript variants encoding the same protein. [provided by RefSeq, Aug 2020]
A study in mice demonstrated that brain injury following clodronate-induced monocyte depletion leads to the emergence of transcriptionally distinct CD115+/Ly6Chi monocyte subsets, including immunoregulatory monocytes enriched for Apoe and Chil3 and a unique neutrophil-like monocyte cluster defined by granule genes Elane, Prtn3, MPO, and Ctsg [Gudenschwager Basso et al. DOI:10.1186/s12974-024-03032-8].